NCT00606099View on ClinicalTrials.gov

Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2009

Conditions
Chronic Hepatitis B
Interventions
DRUG

telbivudine

To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.

DRUG

adefovir dipivoxil

Active Comparator

Trial Locations (3)

11355

Novartis, Flushing

20166

Novartis, Sterling

30308

Novartis, Atlanta

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY